Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Net Margin (2022 - 2025)

Historic Net Margin for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to 124.62%.

  • Atara Biotherapeutics' Net Margin fell 701000.0% to 124.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.4%, marking a year-over-year increase of 1482300.0%. This contributed to the annual value of 66.23% for FY2024, which is 31575500.0% up from last year.
  • According to the latest figures from Q3 2025, Atara Biotherapeutics' Net Margin is 124.62%, which was down 701000.0% from 13.58% recorded in Q2 2025.
  • Atara Biotherapeutics' Net Margin's 5-year high stood at 38.73% during Q1 2025, with a 5-year trough of 33790.5% in Q4 2022.
  • For the 4-year period, Atara Biotherapeutics' Net Margin averaged around 3694.3%, with its median value being 124.62% (2025).
  • Data for Atara Biotherapeutics' Net Margin shows a peak YoY increase of 323629600bps (in 2023) and a maximum YoY decrease of -74661000bps (in 2023) over the last 5 years.
  • Quarter analysis of 4 years shows Atara Biotherapeutics' Net Margin stood at 33790.5% in 2022, then skyrocketed by 96bps to 1427.54% in 2023, then surged by 97bps to 38.75% in 2024, then crashed by -222bps to 124.62% in 2025.
  • Its Net Margin was 124.62% in Q3 2025, compared to 13.58% in Q2 2025 and 38.73% in Q1 2025.